Study guide

1.2 Controlled Drugs and Substances Act (CDSA) & Controlled Substances Regulations (CSR)

PEBC Pharmacist Qualifying Examination Part I MCQ

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Canadian Pharmacy Regulatory Framework & Federal Legislation

1.1 Food and Drugs Act, Regulations, and Health Canada Oversight 1.2 Controlled Drugs and Substances Act (CDSA) & Controlled Substances Regulations (CSR) 1.3 NAPRA Drug Scheduling Framework & National Model Standards of Practice

2 Chapter 2: Ethics, Scope of Practice & Safety Culture

2.1 Professional Ethics, Fiduciary Duty & Health Information Privacy 2.2 Expanded Scope of Practice: Minor Ailments Prescribing, Renewals & Injections 2.3 Equity, Diversity, Inclusion, Cultural Safety & Continuous Quality Improvement

3 Chapter 3: Pharmaceutical Calculations & Posology

3.1 Concentrations, Dilutions, Alligations & Reconstitution 3.2 Dosing by Weight/BSA, Days Supply & Pediatric/Geriatric Dose Adjustments 3.3 IV Infusion Rates, Drop Factors, Osmolarity & Creatinine Clearance (Cockcroft-Gault)

4 Chapter 4: Compounding, Dispensing & Product Integrity

4.1 Non-Sterile Compounding & Beyond-Use Dating (NAPRA Standards) 4.2 Sterile Preparations & Hazardous Drug Handling (NAPRA / NIOSH Principles) 4.3 Prescription Verification, Auxiliary Labeling, Cold Chain & Medication Incident Prevention (ISMP Canada) 4.4 Dispensing Operations: Interchangeability, Adjudication, Compliance Packaging, Release & Inventory Control

5 Chapter 5: Clinical Pharmacology & Pharmacokinetics

5.1 Pharmacokinetic Principles: Clearance, Volume of Distribution, Half-life & Steady State 5.2 Cytochrome P450 Enzymes, Transporters & Significant Drug-Drug Interactions 5.3 Therapeutic Drug Monitoring (TDM), Narrow Therapeutic Index Drugs & Toxicities

6 Chapter 6: Evidence-Based Medicine & Literature Appraisal

6.1 Study Designs, Bias & Levels of Evidence in Clinical Research 6.2 Biostatistics: ARR, RRR, NNT, NNH, Confidence Intervals & P-values 6.3 Applying Canadian Practice Guidelines to Clinical Decision-Making 6.4 Drug Information Practice, Diagnostic Test Accuracy & Pharmacoeconomics

7 Chapter 7: Cardiovascular Pharmacotherapy: Hypertension, Dyslipidemia & CAD

7.1 Hypertension Management (Hypertension Canada Guidelines, Targets & Regimens) 7.2 Dyslipidemia & Atherosclerotic Cardiovascular Disease (CCS Guidelines & Statin Therapy) 7.3 Ischemic Heart Disease & Acute Coronary Syndromes (Antiplatelet & Antianginal Therapy)

8 Chapter 8: Cardiovascular Pharmacotherapy: Heart Failure, Arrhythmias & Anticoagulation

8.1 Heart Failure with Reduced & Preserved Ejection Fraction (GDMT & Monitoring) 8.2 Atrial Fibrillation, Arrhythmias & Rate vs. Rhythm Control 8.3 Venous Thromboembolism & Anticoagulation Therapy (DOACs, Warfarin & Thrombosis Canada)

9 Chapter 9: Endocrine & Metabolic Disorders

9.1 Type 2 Diabetes: Glycemic Targets, Non-Insulin Pharmacotherapy (Diabetes Canada) 9.2 Insulin Regimens, Type 1 Diabetes, Hypoglycemia & Diabetic Emergencies (DKA/HHS) 9.3 Thyroid Disorders & Osteoporosis (Diagnostic Parameters & Therapeutic Management)

10 Chapter 10: Respiratory & Gastrointestinal Disorders

10.1 Asthma Management & Exacerbations (CTS Guidelines, Relievers & Controllers) 10.2 Chronic Obstructive Pulmonary Disease (COPD) & Inhaler Delivery Systems 10.3 Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease & GI Bleeding 10.4 Lower GI & Liver Disorders: Constipation, Diarrhea, IBS, IBD & Cirrhosis

11 Chapter 11: Infectious Diseases & Antimicrobial Stewardship

11.1 Respiratory Tract Infections: Otitis, Sinusitis, Pharyngitis, CAP & HAP 11.2 Urinary Tract, Skin/Soft Tissue & Sexually Transmitted Infections 11.3 Systemic Infections, Clostridioides difficile & Antimicrobial Stewardship Principles 11.4 HIV Prevention & Treatment, Viral Hepatitis, Tuberculosis & Fungal Infections

12 Chapter 12: Central Nervous System & Mental Health

12.1 Major Depressive Disorder & Anxiety Disorders (First-Line Agents & Safety) 12.2 Bipolar Disorder, Schizophrenia & Psychopharmacology Monitoring 12.3 Epilepsy, Seizure Types, Antiseizure Medications & Neuropathic Pain 12.4 Dementia, Parkinson Disease, Migraine, Insomnia & Restless Legs Syndrome

13 Chapter 13: Special Populations, Pain Management & Substance Use

13.1 Acute & Chronic Pain Management: Multimodal Analgesia & Opioid Stewardship 13.2 Substance Use Disorders: Opioid Agonist Therapy, Harm Reduction & Alcohol Withdrawal 13.3 Special Populations: Pharmacotherapy in Pregnancy, Lactation & Geriatrics (Deprescribing / Beers) 13.4 Palliative Care & Pediatric Pharmacotherapy

14 Chapter 14: Renal, Rheumatologic, Hematologic & Oncology Supportive Care

14.1 Chronic Kidney Disease, Acute Kidney Injury & Electrolyte Disorders 14.2 Osteoarthritis, Rheumatoid Arthritis & Gout 14.3 Anemias & Oncology Supportive Care

15 Chapter 15: Minor Ailments, Dermatology and Women's & Men's Health

15.1 Minor Ailments I: Allergic Rhinitis, Colds & Influenza, Eye and Ear Conditions 15.2 Minor Ailments II: Acne, Dermatitis, Psoriasis, Lice, Scabies & Sun Protection 15.3 Women's & Men's Health: Contraception, Emergency Contraception, Menopause, BPH, ED & Overactive Bladder

16 Chapter 16: Immunization & Health Promotion

16.1 Immunization Practice: NACI Recommendations, Administration, Cold Chain & Adverse Events 16.2 Health Promotion: Smoking Cessation, Weight Management, Screening & Social Determinants of Health

17 Chapter 17: Patient Care Process, Communication & Stewardship

17.1 The Patient Care Process: Assessment, Care Planning & Patient Interviewing 17.2 Patient Education, Device Counselling, Health Literacy & Overcoming Barriers 17.3 Interprofessional Collaboration, Pharmacy Workflow, Team Delegation & Drug Shortage Stewardship

1.2 Controlled Drugs and Substances Act (CDSA) & Controlled Substances Regulations (CSR)

Key Takeaways Explain This Topic AI

The Controlled Substances Regulations (CSR) came into force on October 1, 2026, replacing the Narcotic Control Regulations, the BOTSR and Parts G and J of the Food and Drug Regulations.

CSR Schedules 1 to 4 classify narcotics, controlled drugs, targeted substances and restricted drugs; zolpidem is a targeted substance, while zopiclone and pregabalin are not controlled.

A practitioner may give a written or verbal prescription for any non-restricted controlled substance, and a pharmacist or pharmacy technician may receive and record verbal prescriptions.

Pharmacists may extend a controlled-substance prescription where provincially authorized, and pharmacists or technicians may transfer it, each within 2 years of the pharmacy receiving it.

A loss or theft needs a written report to Health Canada within 10 days, and destruction needs a qualified witness plus a signed joint declaration.

Last updated: October 2026

Controlled Drugs and Substances Act (CDSA) and the Controlled Substances Regulations (CSR)

Controlled substances sit on top of the ordinary prescription rules. The Controlled Drugs and Substances Act (CDSA) creates the offences (possession, trafficking, production, import and export) and lists substances in its schedules. Regulations made under the Act say who may lawfully handle those substances and how.

Important

On October 1, 2026 , the Controlled Substances Regulations (CSR, SOR/2025-242) came into force. They replaced four older instruments at once: the Narcotic Control Regulations (NCR), the Benzodiazepines and Other Targeted Substances Regulations (BOTSR), and Parts G and J of the Food and Drug Regulations . The CSR also made permanent the pharmacist flexibilities that a subsection 56(1) class exemption had allowed since 2020; that exemption ended on September 30, 2026. Older textbooks and question banks still teach the NCR "straight narcotic / verbal prescription narcotic" rules. Learn the CSR rules first, and recognise the legacy terms when you see them.

The CDSA Schedules vs. the CSR Schedules

The two sets of schedules do different jobs:

CDSA Schedules I–VI decide criminal penalties. Schedule I includes most opioids, cocaine, amphetamines and methamphetamine. Schedule III includes hallucinogens such as LSD and psilocybin, as well as methylphenidate. Schedule IV includes benzodiazepines, barbiturates and anabolic steroids. Schedule VI lists precursor chemicals such as ephedrine and pseudoephedrine used in illicit synthesis.

CSR Schedules 1–4 decide the practice rules for pharmacists, practitioners and licensed dealers. Every controlled substance falls into exactly one CSR class.

CSR Schedule Class Common pharmacy examples

1 Narcotics Morphine, hydromorphone, oxycodone, fentanyl, methadone, buprenorphine, codeine, tramadol, tapentadol, ketamine, nabilone

2 Controlled drugs Amphetamine salts, lisdexamfetamine, methylphenidate, phenobarbital, butalbital, testosterone and other anabolic steroids

  • 3 Targeted substances Benzodiazepines (lorazepam, diazepam, clonazepam, midazolam), zolpidem, carisoprodol
  • 4 Restricted drugs Psilocybin, LSD, MDMA and similar substances with no approved therapeutic use

Tip

Zopiclone and pregabalin are not controlled substances in Canada. They are prescription drugs (Prescription Drug List), so ordinary provincial prescription rules apply. Zolpidem, by contrast, is a targeted substance (CSR Schedule 3). Exam items like to test exactly this contrast.

Restricted drugs (Schedule 4) cannot be sold to patients through a community pharmacy. Access runs through clinical trials, the Special Access Program combined with a subsection 56(1) exemption, or a letter of authorization.

Sale to an Individual: What Counts as a Valid Prescription

Under CSR section 98(1) , a pharmacist may sell or provide a controlled substance to an individual when all of these conditions are met:

The sale is for the individual's own use, for another individual, or for an animal.

The substance is a finished product (DIN product or a pharmacy compound) that does not contain a restricted drug.

Before the sale, the pharmacist receives one of the following:

  • a written prescription presented by the patient;
  • a written or verbal prescription directly from the practitioner; or

from another pharmacist or pharmacy technician, the written prescription or a copy of the record of a verbal prescription (a transfer).

This rule applies to all four non-restricted schedules , including Schedule 1 narcotics such as oxycodone and hydromorphone. The old NCR barrier that banned verbal prescriptions for "straight" narcotics is gone federally. A pharmacist or a pharmacy technician may receive and record a verbal prescription (s. 117). The record includes:

  • the name of the person who received it;
  • the prescriber's name and practice address;
  • the date received;
  • the drug name, form, strength and quantity (plus DIN for a finished product); and

any authorized refills and intervals.

Warning

Federal law is the floor, not the ceiling. Provincial prescription monitoring programs, college standards and hospital policies can still require written or specially formatted prescriptions for some opioids and stimulants. When a provincial rule is stricter, the stricter rule governs.

Only a pharmacist sells or provides the controlled substance to the patient. Technicians may prepare, compound and record, but the final hand-off and counselling stay with the pharmacist.

Verification of identity (s. 103). Anyone receiving an order or prescription for a controlled substance must verify the person's name and title. They must also verify the person's signature if the pharmacist does not know it. Forged or altered prescriptions remain a common diversion route. Call the prescriber's office using an independently confirmed number, not the number printed on the prescription.

Refills, Part-Fills, Extensions, Transfers, and Substitution

The CSR replaced several NCR and BOTSR restrictions with a single set of rules:

Activity Legacy rule (NCR / BOTSR) CSR rule (from October 1, 2026)

Refills NCR: no refills on narcotics (part-fills only). BOTSR: refills allowed within 1 year No federal refill ban by schedule. Refills authorized on the prescription are recorded (s. 113, s. 118)

Part-fills Allowed if the total quantity and intervals were written Still allowed. Dispense in portions within the total quantity prescribed

Extension (renewal) Not permitted federally (allowed temporarily under the 2020 exemption) Pharmacist may extend if provincially authorized; new expiry no later than 2 years after the pharmacy received the prescription (s. 101)

Transfer NCR: narcotics not transferable. BOTSR: targeted substances transferable once Pharmacist or technician may transfer to another pharmacist or technician within 2 years of receipt, with no count limit (s. 102)

Substitution Not addressed A pharmacist may substitute one controlled substance for another only if provincial law authorizes it (s. 100)

Practice consequences:

Extension is a pharmacist act; both parts must be satisfied. The province must allow pharmacist renewals or adaptations, and the CSR two-year outer limit applies.

Transfers move the original written prescription or the verbal-prescription record. Both the sending and the receiving professional record:

  • their names and practice addresses;
  • the prescription number;
  • the dates;
  • the date of the last fill; and

the refills remaining (s. 119).

Substitution depends on the province. For example, Ontario pharmacists may adapt but may not therapeutically substitute a controlled substance. A pharmacist who substitutes must record the original and substitute drug (s. 115).

Low-Dose Codeine Without a Prescription

Under CSR s. 98(2) , a pharmacist may sell a low-dose codeine product without a prescription only when all of these conditions are met:

Strength: not more than 8 mg codeine phosphate per solid unit , or 20 mg per 30 mL of liquid.

Other ingredients: the product contains two or three additional non-narcotic medicinal ingredients at the minimum doses the regulation sets.

Use: the pharmacist has reasonable grounds to believe it will be used only for recognized medical purposes.

Labelling: the label carries the caution: "This product contains codeine and should not be administered to children except on the advice of a physician, dentist or nurse practitioner."

NAPRA lists these products in Schedule II . They stay behind the counter, and the pharmacist must be involved in the sale. Many provinces add further limits (for example, recording sales or restricting pack sizes), and Health Canada advises against codeine for children under 12.

Storage, Delivery, Loss and Theft, and Destruction

Storage (s. 105, 108): The pharmacist keeps every controlled substance in a secure location . Only people the pharmacist authorizes may access it, and all reasonable security measures must be taken.

Delivery (s. 106–107): Pharmacists and technicians may deliver, send or transport controlled substances. They must use a trackable method and secure the package during transit.

Loss or theft (s. 109): An employee or agent who becomes aware of a loss or theft tells the pharmacist immediately. The pharmacist then sends a written report to the Minister (Health Canada) within 10 days of becoming aware. Report theft or break-ins to police as well. The report cannot be used to incriminate the pharmacist in other criminal proceedings.

Destruction (s. 110, 121): Only a pharmacist or pharmacy technician may destroy a controlled substance in a pharmacy, and the following conditions apply:

Another pharmacist, technician or intern, a practitioner, or another health professional must witness it.

The method must meet environmental law.

Both people sign a joint declaration immediately afterwards, with printed names.

No prior federal approval is needed.

Patient-returned substances that are not destroyed on site go to a licensed dealer specialized in destruction .

Patient returns are kept in a marked collection container in a secure area (s. 104). They are never returned to dispensing stock.

Records and Retention

The CSR require records of every controlled-substance event:

  • ordering and receipt (s. 111);
  • sales to individuals (s. 113), compounding (s. 114) and substitution (s. 115);
  • written and verbal prescriptions (s. 116–117);
  • refills and extensions (s. 118) and transfers (s. 119);

deliveries (s. 120) and destruction (s. 121).

Records must:

  • allow an audit at any time (s. 122);
  • be kept for 2 years , with sales documents filed separately in date and number order (s. 123);
  • stay legible, indelible and retrievable at the pharmacy (s. 124–125); and

be produced on request by the Minister (s. 126).

Pharmacists practising in hospitals follow the hospital provisions of the CSR rather than the community pharmacy sections.

Clinical & Regulatory Case Scenario: Three Requests on the First Day Under the CSR

On October 2, 2026, a community pharmacy in a province that authorizes pharmacist prescription renewals receives three requests:

A telephone prescription for hydromorphone 2 mg tablets, #20, from a known surgeon. A technician takes the call, confirms the prescriber's identity through the clinic's listed number, and records the s. 117 details. The pharmacist reviews the opioid history in the provincial monitoring program and counsels the patient. The pharmacist then dispenses, because federal law now permits verbal narcotic prescriptions and the provincial standard does not prohibit them.

A request to transfer a lorazepam prescription for the third time. Under BOTSR this would have been refused, because a targeted-substance prescription could be transferred only once. Under s. 102 the technician may transfer it, because the prescription is within 2 years of receipt. The technician sends the written prescription or verbal record and documents the remaining refills.

A bin of expired fentanyl patches. The pharmacist denatures them, with a pharmacy technician as witness. Both sign and date a joint declaration with printed names, and the destruction record is filed with the controlled-substance records for 2 years.